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Background: Cancer is a non-communicable disease that occurs following a mutation in the
genes which control cell growth. Breast cancer is the most diagnosed cancer among South
African women and a major cause of cancer-related deaths worldwide. Photodynamic
therapy (PDT) is an alternative cancer therapy that uses photochemotherapeutic agents,
known as photosensitizers. Drug-delivery nanoparticles are commonly used in nano-
medicine to enhance drug-therapeutic efficiency. This study evaluated the photodynamic
effects following treatment with 0.3 mM multiple particles delivery complex (MPDC) and
irradiated with a laser fluence of 10 J/cm2 using a 680 nm diode laser in a breast cancer cell
line (MCF-7).
Methods: Cell damage was assessed by inverted light microscopy for cell morphology; the
Apoptox-Glo triple assay was used for cell viability, caspase activity and identification of
cytodamage markers; flow cytometric analysis for cell death pathways and mitochondrial
membrane potential; the enzyme linked immunosorbent assay (ELISA) for cytochrome C
release; and real-time reverse transcriptase polymerase chain reaction (RT-PCR) array for
gene expression.
Results: Laser activated-MPDC induced a significant change in morphology of PDT-treated
cells, with the appearance of apoptotic like morphological features. An increase in cyto-
toxicity, caspase activity, cell depolarization and cytochrome C release were identified in
PDT-treated cells. Finally, the upregulation of BAX, BCL-2, CASP-2 and ULK-1 genes was
observed.
Conclusion: The MPDC yielded a successful and stable hybrid agent with potent photody-
namic abilities.Cancer is a non-communicable disease that is characterized million projected deaths in 2030 [1,2]. In Africa, few resourcesby abnormal cell proliferation and subsequent cellular dam-
age. Cancer has become a major life threatening disease in
both the developed and developing world, with more than 11tre, Faculty of Health Sci
Abrahamse).
g Gung University.
ublishing services by Else
/by-nc-nd/4.0/).are allocated to the fight against cancer and as a result the
disease accounts for numerous deaths. Currently, cancer
causes more deaths than tuberculosis, the acquired immuneences, University of Johannesburg, P.O. Box 17011, Doornfontein,
vier B.V. This is an open access article under the CC BY-NC-ND
Fig. 1 Schematic representation of the MPDC, consisting of a
gold-encapsulated dendrimer and 38 Sulfonated Zinc-
Phthalocyanine mix.
Table 1 Laser parameters for irradiation.
Parameters Diode laser
Manufacturer Oriel Corporation
Wavelength 680 nm
Wave emission Continuous
Spot size 9.1 cm2
Output power 52 mW
Power density 5.73 mW/cm2
Fluence 10 J/cm2
Irradiation time 33 min 40 s
At a glance commentary
Scientific background on the subject
Cancer is a major life threatening disease that requires
vigorous treatment. Photodynamic therapy is an alter-
native therapy that uses photochemotherapeutic agents
and low intensity laser irradiation to stimulate cell
damage in the presence of molecular oxygen. This study
investigated the effect of a multiple particle delivery
complex in MCF7 cells.
What this study adds to the field
The novel multiple particle delivery complex (MPDC),
consisting of sulfonated Zinc-Phthalocyanine and gold
nanoparticle encapsulated dendrimers, yielded a suc-
cessful and stable hybrid agent with potent photody-
namic abilities. Conjugation could improve therapeutic
outcomes to achieve better targeted therapy or better
delivery to cancer cells, and increased cancer cell
sensitivity to treatment.
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Abnormal cell proliferation within the breast glands is known
as breast cancer. This form of cancer is the most diagnosed
cancer among South African women and a major cause of
cancer-related deaths worldwide. Treatments for cancer have
evolved from palliative to conventional therapies [3,5,6].
Photodynamic therapy (PDT) is an alternative cancer ther-
apy that uses a photosensitizer (PS) and low intensity laser
irradiation to stimulate cell damage in the presence of
molecular oxygen [7]. The anticancer effects of PDT and the
generation of reactive oxygen species (ROS) depends on the
photophysical and photobiological abilities of the PS.
Generated ROS can induce cell damage by various cell death
mechanisms [8,9].
Research and development of new PSs is ongoing and crucial
for the efficiency of PDT [10]. Nanotechnology is the engineering
of small particles and is an interdisciplinary field set to revolu-
tionize the fight against cancer by providing exceptional inter-
action of cancer cells with nanomaterials at both superficial and
intracellular levels [11,12]. Nanoparticles (NPs) have been used in
medical applications as imaging agents, therapeutic agents,
diagnostic agents, active implants and drug-delivery agents [13].
NPs have attracted the attention of many researchers because of
their high surface to mass ratio, quantum properties, and ca-
pacity to absorb and carry other compounds [14]. Drug-delivery
NPs are commonly used in nanomedicine and offer additional
benefits including the enhancement of drug-therapeutic effi-
ciency and pharmacological properties by altering pharmacoki-
netics, improving drug hydro-solubility, drug half-life,
bioavailability and target cell specificity [15]. This study looked at
the mechanisms of breast cancer cell (MCF-7) damage mediated
by aMPDC,which consisted of a sulfonated Zinc-Phthalocyanine
mix (ZnPcSmix) and gold nanoparticle encapsulated dendrimers
(AuDENPs) [Fig. 1].Materials and methods
Cell culture and treatment
MCF-7 breast cancer cells (ATCC: HTB-22™, Lot Number:
60731981) were cultivated in Dulbecco's Modified Eagle Me-
dium (DMEM, Gibco, 41966). The culture media was enriched
with 10% fetal bovine serum (FBS, Gibco, 10106-169), 1%
Amphotericin-B (Sigma, A2942) and 1% Penicillin-
streptomycin (Sigma, P4333). Cells were incubated at 37 C in
5% CO2 and 85% humidity. Upon reaching confluency, cells
were washed twice with Hank's Balance Salt Solution (HBSS,
Gibco, 14065-056) before TryplEtm Express (Gibco, 12604) was
used to detach the cells from the culture flasks using 1 ml/
25 cm2. For experimental purposes, 5 105 MCF-7 cells (in 2ml
culture medium) were seeded in 3.4 cm diameter culture
dishes and incubated for 4 h to allow the cells to attach. Fourth
generation AuDENPs were mixed with ZnPcSmix at a ratio of
1:37.86 (v/v). The resultant particles is referred to as amultiple
particles delivery complex (MPDC). Cells were treated with
0.3 mM MPDC and irradiated at a fluency of 10 J/cm2 using a
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 2 5 4e2 6 4256680 nm diode laser [Table 1]. Post-irradiation, the incubation
periods of 3 and 24 h were considered for gene expression and
biological assays, respectively.
Cell morphology
Morphological changes were examined in all control (no
MPDC and no irradiation) and experimental groups 24 h post-
irradiation. A CKX41 inverted light microscope (Olympus,
Wirsam) connected to a camera was used to observe and
capture qualitative changes with the analysis get IT software.
Once digital images were captured, cells were detached and
re-suspended for further biological analysis.
Biological assays
The ApoTox-Glo™ Triplex Assay (Promega, G6320) was per-
formed to assess cell viability, cytotoxicity and caspase 3/7
activation and cleavage. A density of 2  105 cells per well was
seeded and 20 ml of viability/cytotoxicity reagent was added,
containing both glycyphenylalanyl-aminofluorocoumarin (GF-
AFC) and bis-alanylalanyl-phenylalnyl-rhodamine 100 (AAF-
R110) substrates for cell viability and cytotoxicity measure-
ments respectively. Plates were placed on an orbital shaker
(Heidolph Polymax Orbital, Labotec, 1040) set at 250 rpm for
1 min. Viable cells show a decrease in AFC fluorescence, while
dead cells show an increase in R110 fluorescence. The mixture
in a 96-well plate was incubated for 1 h at 37 C before the
fluorescence signals were recorded with 400Ex/550Em filters for
viability and 485Ex/535Em filters for cytotoxicity. Thereafter,
caspase 3/7 activity was measured by adding 100 ml of the
Caspase-Glo 3/7 reagent to all wells and the luminescence
signal was measured after 30 min of incubation at room tem-
perature. All signal measurements were performed using the
Victor3 microplate reader (PerkineElmer).
Changes in mitochondrial membrane potential or depo-
larization of the mitochondrial transmembrane potential
(DJm) is associated with apoptosis, and the percentages of
normal (polarized mitochondria) and damaged (depolarized
mitochondria) cell populations were evaluated following
treatment. Depolarized cells are unable to take up JC-1 stain
and do not fluoresce in the red channel. Cells were detached
as previously described, re-suspended in 1 ml HBSS and
centrifuged at a speed of 400  g for 5 min at a temperature of
4 C. The supernatant was discarded and cells were re-
suspended in 0.5 ml of a fresh JC-1 working solution (551302
Mitochondrial Membrane Potential Detection JC-1 kit, BD
Biosciences) and thoroughly mixed. Then the mixture was
incubated at 37 C in a CO2 incubator for 10 min, followed by
the addition of 1 ml of 1  assay buffer. The combination was
mixed and centrifuged for 5 min at 400  g. Again, the su-
pernatant was discarded, 0.5ml of 1 assay buffer was added,
the solution was vortexed and centrifuged in the same
manner. Cells were re-suspended in 0.5 ml 1  buffer and the
cells in the pellet suspended by vortexing. Analysis was done
using the FACSCAria flow cytometer (BD Biosciences).
Cytochrome C is an apoptogenic component required for
further apoptotic events such as caspase-3 activation and
DNA fragmentation. Mitochondrial damage and leakage wereassessed with an enzyme linked immunoassay (eBioscience,
BMS 263 human cytochrome C Platinum ELISA kit) to detect
the level of cytosolic cytochrome C in various treated samples.
Cells were detached from the plate, re-suspended in HBSS,
centrifuged for 15 min at a speed of 217  g and the super-
natant was discarded. Thereafter, cells were re-suspended in
1 ml of cold phosphate buffer solution and centrifuged for
5 min at 398  g. Cells were lysed by incubating with 0.5 ml of
lysis buffer for 1 h at room temperature. Then, cells were
centrifuged for 15 min at 217  g and a 50-fold dilution of the
supernatant was done by removing 5 ml of the supernatant
and adding it into to a 1.5 ml tube with 245 ml of 1  assay
buffer. Samples (lysate supernatants) were further diluted by
making a 1:2 dilution in assay buffer; 150 ml of sample was
added to an equal volume of 1  assay buffer, and a volume of
100 ml was added to the wells in a 96-well plate. Blank wells
contained 100 ml of 1  assay buffer added in duplicate, and all
standards and samples were also added in duplicate. A vol-
ume of 50 ml biotin-conjugated anti-human cytochrome C
antibody was added to all the wells and the microplate was
covered with an adhesive film and incubated for 2 h at room
temperature. Thereafter, the microplate was rinsed three
timeswith 400 ml of wash buffer and 100 ml of Streptavidin-HRP
secondary antibodywas added to all the wells. Themicroplate
was covered with an adhesive film and incubated for 1 h at
room temperature. Then, the wells were washed three times
with 400 ml of wash buffer, 100 ml of tetramethyl-benzidine
(TMB) substrate was added and the plate was incubated at
room temperature for 10min. Lastly, the reactionwas stopped
by adding 100 ml of stop solution and the absorbance of each
well was read at 450 nm using the Victor3 microplate reader
(PerkineElmer).
Cells were stained with Annexin V-fluorescein isothiocy-
anate (FITC) and Propidium iodide (PI) (BD Bioscience, 556547)
to determine the mode of cell death. After treatment, cells
were re-suspended, rinsed twice with PBS and then re-
suspended in a 1  assay binding buffer. A volume of
100 ml was transferred into a 15 ml Falcon™ tube and cells
were concurrently incubated with 5 ml of Annexin V-FITC and
PI. The mixtures were incubated in the dark for 5 min on ice.
Then 400 ml of 1  binding buffer was added to all the sam-
ples which were analyzed on the FACSCAria flow cytometer
(BD Biosciences) by reading 10 000 events. Several control
samples were included and prepared for the assay as follows:
cells only without any stain; cells stained with Annexin V-
FITC only; cells stained with PI only; and positive control cells
which included those stained with both Annexin V-FITC and
PI (late apoptotic). An apoptosis positive control was pre-
pared by inducing apoptosis with 1 mg/ml actinomycin D, and
a necrosis positive control with 10% (v/v) hydrogen peroxide
for 24 h.
The real-time reverse transcriptase polymerase chain re-
action (RT-PCR) was used to evaluate the expression of 84
genes following treatment (3 h incubation). Cells were de-
tached and rinsed with PBS to remove all traces of culture
media. Total RNA from untreated, MPDC-treated and PDT-
treated cells was isolated using the RNeasy kit (Qiagen,
74104) with QIA shredder homogenizers (Qiagen, 79654). Cells
were re-suspended in 600 ml RLT buffer and loaded on the QIA
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 2 5 4e2 6 4 257cube (Invitrogen). At the end of the run, 30 ml of eluted RNA
was collected and quantified using the Quant-iT™ RNA Assay
kit (Invitrogen, Q32852) on the Qubit™ fluorometer (Invi-
trogen) according to the manufacturer's protocol. Two stan-
dards were used to calibrate the Qubit™ fluorometer and
sample RNA concentration (mg/ml) was determined.
One microliter of sample RNA was mixed with 99 ml buffer
AE (SABiosciences, 19077) in a quartz cuvette to determine
RNA purity. The buffer consists of 10 mM Tris-Cl and 0.5 mM
EDTA; pH 9.0. The absorbance of each sample was read using
the Biomate 3 spectrophotometer (Thermospectronic,
335904P), and the ratio of the absorbance value at 206 nm over
the value at 208 nm was calculated. All ratio values were be-
tween 1.82 and 2.01. Complementary DNA (cDNA) was reverse
transcribed from 30 ng RNA using the QuantiTect Reverse
Transcription kit, which included genomic DNA (gDNA)
wipeout buffer. gDNA elimination was carried out for 8 min at
42 C and the reaction stopped by placing the tubes on ice.
Thereafter, a reverse transcription reaction with a final vol-
ume of 20 ml was prepared on ice by mixing Quantiscript
Reverse Transcriptase, Quantiscript RT Buffer, RT Primer Mix
and the gDNA elimination reaction (14 ml). The reverse tran-
scription reaction tubes were vortexed and incubated for
15 min at 42 C and then transferred and incubated for
3 min at 95 C to deactivate Quantiscript Reverse Transcrip-
tase. The purity of the cDNA samples was determined after
obtaining the absorbance values and ratios (A260/280 nm)
which were between 1.84 and 1.97. The real-time PCR array
was performed and the synthesized cDNA used as a template.
The expression of 84 genes involved in death cell and
senescence [Table 2] was analyzed using the Human Cell
Death Pathway Finder™ PCR Array (SABiosciences, PAHS-
212A) on the Stratagene Mx3000p. An additional 12 genes
were integrated and consisted of 5 housekeeping genes (B2M,
HPRT1, RPL13A, GAPDH, ACTB) to standardize the genes of
interest, a gDNA control, positive PCR control genes (in trip-
licate) and a reverse transcriptase control gene (in triplicate).
The cDNA samples were diluted to a final volume of 102 ml
with RNase-DNase free water and used to prepare an experi-
mental cocktail by adding the SABiosciences RT2 qPCRmaster
mix according to the manufacturer's protocol. The SABio-
sciences RT2 qPCR Master mix used is designed for the Stra-
tageneMx3000p® and contains RT2 SYBR Green (detected dye)
and ROX (reference dye).Table 2 Functional gene grouping of the human cell death path
212A).
Cell death
Pro-Apoptotic ABL1,
CASP9
(TNFS
Anti-Apoptotic BCL2A
Apoptosis and Autophagy AKT1
Apoptosis and Necrosis ATP6V
Autophagy APP, A
GAA,
(VPS3
Necrosis BMF,
FOXI1
(ADPRTwenty five microliters of the experimental cocktail was
added to each well and the 96 well PCR Array plate was sealed
with optical thin walled 8-cap strips and centrifuged for
1 min at room temperature at 1000  g using a Heraeus
Labofuge 400 centrifuge (Thermo Scientific) to remove all air
bubbles. The run on the Stratagene Mx3000p® was pro-
grammed as follows: 1 cycle, 10 min at 95 C to activate the
HotStart DNA polymerase, and 40 cycles of 15 s and 1 min at
95 C and 60 C respectively (the annealing step).
The instrument software gave the threshold cycle (Ct)
value for eachwell and all Ct values equal to or greater than 35
were considered as negative amplification (absence of
amplicon). A gDNA control well (well H6) with a Ct value
greater than 35 designated absence of gDNA contamination.
Ct values of 20 ± 2 for positive PCR control wells should be
obtained, which indicated successful amplification. The
average Ct values of all 5 housekeeping genes was used by the
software to normalize the 84 genes studied and was sub-
tracted from the gene of interest Ct value. All Ct values were
exported to a blank Excel spread sheet and used with the
SABioscience PCR array Data Analysis Template available
from the SABioscience website with the suitable pathway-
focused genes (PAHS-212A). Fold-change (2(DDCt)) was calcu-
lated by the software by dividing the normalized gene
expression (2(DCt)) of the test sample by the normalized gene
expression (2(DCt)) of the control sample. Fold-change values
greater than one indicate a positive or an up-regulation, and
the fold-regulation is equal to the fold-change, while fold-
change values less than one indicate a negative or down-
regulation. The fold-regulation is the negative inverse of the
fold-change.
Statistics
MCF-7 cells were taken from passage numbers 10e15. Results
were averages of biochemical assays done in duplicate and
repeated 4 times for cell damage analyses (n¼ 4). The oneway
ANOVA (one-tailed test) was done to compare treated cells to
untreated cells, and statistical analysis was done using Sig-
maPlot Version 11.0 (Systat Software Incorporation). Graphs
and tables depicted the obtained means and standard errors
(±SEM) [16]. Statistical values were obtained at the 95th
percentile and indicated as * for all p < 0.05, ** for all p < 0.01
and *** for all p < 0.001. Gene expression experiments wereway finder profiler (updated from SABiosciences, PHAS-
Gene subunits
APAF1, BCL2L11, BIRC2 (c-IAP2), CASP1 (ICE), CASP2, CASP6, CASP7,
, CD40 (TNFRSF5), CD40LG (TNFSF5), CFLAR (CASPER), DFFA, FASLG
F6), GADD45A, NOL3, TNFRSF10A (TRAIL-R).
1 (Bfl-1/A1), BIRC3 (c-IAP1), IGF1R, MCL1, TNFRSF11B, TRAF2, XIAP.
, BAX, BCL2, BCL2L1 (BCL-X), CASP3, FAS (TNFRSF6), TNF, TP53.
1G2, CYLD, SPATA2, SYCP2, TNFRSF1A
TG12, ATG16L1, ATG3, ATG5, ATG7, BECN1, CTSB, CTSS, ESR1 (ERa),
HTT, IFNG, IGF1, INS, IRGM, MAP1LC3A, MAPK8 (JNK1), NFKB1, PIK3C3
4), RPS6KB1, SNCA, SQSTM1, ULK1.
C1orf159, CCDC103, COMMD4, DEFB1, DENND4A, DPYSL4, EIF5B,
, GALNT5, GRB2, HSPBAP1, JPH3, KCNIP1, MAG, OR10J3, PARP1
T1), PARP2, PVR, RAB25, S100A7A, TMEM57, TXNL4B.
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software was utilized to determine the normalization, fold
change (replicate 2(DCt) values) and statistics. The p-value of
fold change of individual gene in all samples was determined
using the student's t-test.Fig. 3 ApoTox-Glo™ Triplex Assay Cell viability assay in
MCF-7 cells using 400/550 ex/em filters. When compared to
untreated control cells, the fluorescent signal of both laser
irradiated and MPDC treated cells did not indicate any major
change in cell viability. The irradiated MPDC exhibited a
significant decrease in cell viability as *** (p ¼ 0.0008).Results
Cell morphology
Morphological features ofMCF-7 cells were assessed following
treatment with MPDC alone, laser irradiation alone and PDT
(treated with MPDC and irradiated) [Fig. 2] and compared to
untreated MCF-7 cells. Neither irradiated cells nor MPDC-
treated cells showed detectable morphological changes.
However, PDT-treated cells changed from a characteristic
epithelial-like appearance and became irregular, with some
cells rounding off and detaching from the culture flask and
appearing as free floating structures.
Biological assays
The ApoTox-Glo™ Triplex Assay was performed to determine
cellular viability, cytotoxicity, and caspase 3/7 activity, and
results of treated cells were compared to those of untreated
cells. Neither irradiation alone nor treatment with MPDC was
able to induce a change in cell viability [Fig. 3], cytotoxicity
[Fig. 4] and caspase activity [Fig. 5]. Thus, the MPDC alone as
well as irradiation alone did not induce toxic effects. In com-
bination with laser irradiation (10 J/cm2), the MPDC induced
marked changes including decreased viability (p ¼ 0.0008),
increased cytotoxicity (p ¼ 0.006) and enhanced caspase ac-
tivity (p¼ 0.0007). TheMPDC had a photodamaging ability as it
only showed a light-dependent toxicity.
Mitochondrial damage or destabilization was evaluated
post-treatment inMCF-7 cells. The percentage of both polarized
(black) and depolarized (gray) mitochondrial membrane po-
tential in each treated cell group was determined andFig. 2 Morphology of untreated, irradiated, MPDC-treated and PDT
irradiated or MPDC treated cells when compared to untreated ce
include an elongation of cells, decrease in cell number, detachmcompared to the respective percentage of polarized or depo-
larized populations in the untreated control cells [Fig. 6]. After
24 h of incubation with the JC-1 fluorometric stain, no signifi-
cant change in mitochondrial membrane potential (polarized
and depolarized cells) was detected when cells were treated
with irradiation alone or MPDC alone. However, a change in
both the polarized and depolarized cell population was
noticeable within PDT-treated cells. PDT-treated cells showed
both an increase in the percentage of depolarized mitochon-
drial membrane and a decrease in the percentage of polarized
membranes (p ¼ 0.008). Thus, loss of mitochondrial membrane
potential or damage was seen with light-activated MPDC.
The release of cytochrome C from the mitochondria is a
critical event in cell damage. Cytochrome C levels in untreated
and treated cells was determined by ELISA 24 h following-treated MCF-7 cells. No morphological change was noted in
lls. The morphology of PDT-treated MCF-7 cells changed,
ent and rounding off (200 magnification).
Fig. 6 Evaluation of mitochondrial membrane potential using
flow cytometric analysis of JC-1 fluorometric stain.
Percentage of polarized (black) and depolarized (gray)
mitochondrial membrane potential were determined and
compared to the percentage of the corresponding
mitochondrial membrane potential of untreated, control
cells. Only the PDT-treated cells showed a change in
mitochondrial membrane potential ** (p ¼ 0.008).
Fig. 4 ApoTox-Glo™ Triplex Cytotoxicity assay in MCF-7 cells
using 485/535 ex/em filters. When compared to untreated
control cells, the fluorescent signal of both laser-irradiated
and MPDC-treated cells did not present any major increased
toxicity. The irradiated MPDC exhibited an increase in
cytotoxicity, shown as ** (p ¼ 0.006).
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irradiation the MPDC was unable to trigger an increase in the
levels of cytochrome C [Fig. 7]. Laser irradiation alonewas also
not enough to lead to such an increase. MPDC coupled with
laser irradiationwas able to initiate cell damage and lead to an
augmented level of cytochrome C (p ¼ 0.0005).
Flow cytometric analysis using Annexin V-FITC and PI was
performed to determine the foremost mode of cell death in
MCF-7 cells following PDT with MPDC. Twenty four hours
post-treatment, MCF-7 cells were stained and prepared for
analysis. Additional controls were included in this experiment
and consisted of MCF-7 cells treated with actinomycin D and
hydrogen peroxide (H2O2) acting as apoptotic and necroticFig. 5 ApoTox-Glo™ Triplex Assay Caspase luminescence
assay in MCF-7 cells. When compared to untreated control
cells, the luminescent signal of both laser-irradiated and
MPDC-treated cells did not present any major increased
caspase activity. The irradiated MPDC displayed a high
luminescent signal, thus an enhanced caspase activity and
is indicated as *** (p ¼ 0.0007).controls, respectively. Different populations of cells were ob-
tained: normal (negative for both Annexin V-FITC and PI),
early apoptotic (positive for Annexin V-FITC and negative for
PI), late apoptotic (positive for both Annexiv V-FITC and PI)
and necrotic (positive for PI and made up of cells that were
subjected to intensive damage). When cells were treated with
actinomycin D or H2O2, significant changes (p ¼ 0.0004 and
0.0007 for normal, p ¼ 0.0005 and 0.03 for early apoptotic,
p ¼ 0.0006 for late apoptotic, and 0.02 and 0.0004 for necrotic
cells) were seen with all cell populations when compared to
their respective population type of the untreated control cells.Fig. 7 Estimation of cytochrome C levels in untreated and
treated MCF-7 cells. Cells treated with laser alone or MPDC
alone did not lead to an increased colorometric signal when
compared to the untreated cells. PDT-treated cells showed a
significant increase shown as *** (p ¼ 0.0005) and evidence of
undergoing cell damage.
Table 3 Percentage of various cell populations following
flow cytometric analysis. The lowest percentage of cell
death (apoptotic and necrotic) and highest percentage of
normal population were obtained with untreated cells.
These apoptotic populations significantly increased
(around 63%, accumulated percentage) in Actinomycin D-
treated cells, and the highest percentage of necrotic
population (42%) was seen with hydrogen peroxide
(H2O2)-treated cells. Experiments were repeated four
times (n ¼ 4) and significant differences are indicated as
*(p ¼ 0.03 and 0.02) and *** (p ¼ 0.0007, 0.0006, 0.0006,
0.0005, 0.0004 and 0.0003) when compared to the
respective population type of the untreated control cells.
Cell populations Untreated
cells
Actinomycin
D-treated cells
H2O2-treated
cells
Normal 89 ± 2.05 26 ± 1.34*** 9 ± 2.52***
Early apoptotic 7 ± 1.69 34 ± 0.49*** 16 ± 2.62*
Late apoptotic 3 ± 2.65 29 ± 0.12*** 33 ± 1.55***
Necrotic 1 ± 1.23 11 ± 1.63* 42 ± 1.02***
± represents standard error.
Fig. 8 Gene expression profiles of PDT-treated MCF-7 cells
with 0.3 mM MPDC and 10 J/cm2 was analyzed using the
SABiosciences Human Cell Death Pathway Finder Profiler™
PCR Array System. PDT-induced changes in gene expression
and BAX, BCL-2, CASP-2 and ULK-1 genes were significantly
up-regulated as represented in the volcano plot. In the
volcano plot, the horizontal line designates the target
threshold (p ¼ 0.05) and vertical lines, the fold change
(central) and target fold change threshold (peripheral) in
gene expression.
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 2 5 4e2 6 4260These treatments were able to induce cell death with
apoptosis being more pronounced with treatment with acti-
nomycin D as expected [Table 3]. Cells treated with laser
irradiation alone or MPDC alone did not result in a significant
change when compared to their respective population of un-
treated cells [Table 3]. However, PDT-treated cells showed
significant changes with all populations (p ¼ 0.0006 for
normal, p ¼ 0.003 for late and early apoptotic, and p ¼ 0.02
for necrotic cells), with the apoptotic population being the
most prominent (59% accumulated percentage) [Table 4].
Real-time RT-PCR was used to determine the regulation of
84 genes involved in cell death 3 h following treatment with
0.3 mM MPDC alone or with PDT. MCF-7 cells treated with
0.3 mM MPDC alone showed no significant up- or down-
regulation of any genes as compared to the untreated con-
trol cells. The gene expression analysis of PDT-treated MCF-
7 cells showed that BAX (p ¼ 0.035), BCL2 (p ¼ 0.044), CASP2
(p ¼ 0.006) and ULK-1 (p ¼ 0.038) were significantly up-
regulated when compared to the untreated control cells
[Fig. 8].Discussion
Not only does various types of cancer cells react differently to
different PSs, but cells also respond differently to diverseTable 4 Percentage of various cell populations following flow c
(apoptotic and necrotic) were obtained with untreated and irra
increased (around 65%) in MPDC- and PDT-treated cells. Exper
differences are shown as *(p¼ 0.02), ** (p ¼ 0.003) and *** (p ¼ 0
the untreated control cells.
Cell populations Untreated cells Irradiated c
Normal 89 ± 2.05 91 ± 1.11
Early apoptotic 7 ± 1.69 6 ± 0.29
Late apoptotic 3 ± 2.65 2 ± 2.45
Necrotic 1 ± 1.23 1 ± 2.15
± represents standard error.concentrations of PSs, wavelengths, power density and flu-
ence of irradiation, and uptake of PSs. Previous work on the
effects of PDT using ZnPcSmix on different cell lines has been
conducted, and all results obtained were cell specific
[7,17e27]. Hence, for each different type of cancer that is
investigated, both PS concentration and laser irradiation flu-
ence is determined in a dose response manner prior to con-
ducting further investigation with respect to biological
responsiveness of cells. The inverted light microscopic anal-
ysis was performed following treatment with both MPDC and
laser irradiation in MCF-7 cells. Only laser-activated MPDC in
the PDT-treated cells showed a significant change in cell
morphology as compared to the untreated control cells. Some
cells detached from the culture surface and appeared as free-
floating structures, an indication of cell damage and con-
firming the ability of the MPDC to yield cytodamaging effects
in MCF-7 cancer cells. Lee and co-workers (2009) confirmed
cell morphological changes when conjugated AuNPs were
used in lung cancer targeted therapy [28]. Another similar
analysis was conducted and indicated that using AuNPs-ytometric analysis. The lowest percentage of cell death
diated controls. These apoptotic populations significantly
iments were repeated four times (n ¼ 4) and significant
.0006) when compared to the respective population type of
ells MPDC-treated cells PDT-treated cells
86 ± 0.32 32 ± 1.06***
9 ± 2.12 29 ± 1.56**
4 ± 3.05 30 ± 1.74**
1 ± 1.84 9 ± 2.33*
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 2 5 4e2 6 4 261targeted therapy in liver and lung cancer led to morphological
changes and the appearance of apoptotic-like characteristic
morphological features [29].
The ApoTox-Glo™ Triplex Assay was performed to deter-
mine cell viability, cytotoxicity and caspase 3/7 activity after
treatment. It was revealed that light-activated MPDC promp-
ted decreased cell viability and increased cytotoxicity and
caspase 3/7 activity inMCF-7 cells. This showed that theMPDC
in its active form following irradiation was able to induce
significant damaging effects. Other studies have reported
similar findings using various complexes containing AuNPs in
different cancer cell lines. Decreased cell viability of breast,
bladder and prostate cancer cells was seen following irradia-
tion of drug-coated AuNPs for fibroblast growth factor 1 tar-
geted cancer therapy [30]. Both 5 and 10 nm AuNPs containing
compounds were endocytosed by A549 lung cancer cells
leading to the inhibition of cell growth and increased cyto-
toxicity. These effects seemed to disappear when 20 and
40 nm sized compounds were utilized [31]. In another targeted
therapy study, decreased viability, increased anti-proliferative
and pro-apoptotic activity (such as increased caspase activity)
were identified as the induced tumor suppressor response in
breast cancer cells [32].
Results from this present study showed thatmitochondrial
integrity was not maintained after MPDC-mediated PDT in
MCF-7 cells, as a change in the percentage of polarized and
depolarized mitochondrial membrane potential was detected
and indicated mitochondrial damage. A number of studies
have reported that treatments using drugs, which localize in
mitochondria, damage these cellular organelles triggering cell
death through apoptotic pathways. Wen and co-workers
(2013) reported that cancer treatment that targeted mito-
chondria led to dysfunctioning mitochondria with a shift in
energy generation from oxidative phosphorylation to glycol-
ysis, and noted high levels of ROS in various cell lines [33].
Treatment provoked a change in mitochondrial membrane
potential, ROS levels and intracellular levels of ATP [34]. Pan-
cratistin, an anti-cancer agent, triggered a decrease in mito-
chondrial membrane potential and led to the initiation of
apoptosis in colorectal carcinoma cell lines [35].
NPs combined with therapeutic agents induced depolari-
zation of the mitochondrial membrane potential, trans-
location of apoptosis inducing factor (AIF) and activation of
caspase activity [36]. Rhodamine-123 accumulated in mito-
chondria and this accumulation lead to the disruption of
mitochondrial membrane potential in kidney and breast
cancer cells [37,38]. A similar disruption in mitochondrial
membrane potential was seen with treatments using com-
pounds such as RH1, edelfosine, doxobicin and curcumin as
anti-cancer agents [39e42].
Mitochondrial damage has been linked to the release of
cytochrome C. In this study, we used ELISA to determine the
level of cytochrome C. It was found that the release of cy-
tochrome C significantly increased after treatment with
MPDC and laser irradiation in the PDT-treated cells. This
concurs with work done by Heiligtag and associates (2002)
when cerulenin, an anti-cancer agent, was able to damage
mitochondria which led to the release of cytochrome C and
the induction of apoptosis [43]. The induced release of cyto-
chrome C is an important event for the activation ofapoptotic cascades and caspase-dependent cell death [44,45].
The release of cytochrome C from the mitochondria was
detected early and seemed to be critical for the initiation of
cell death [46].
Annexin V-FITC and PI flow cytometric analysis estab-
lished that apoptosis was the major induced cell death
response after MPDC-mediated PDT in MCF-7 cells. The in-
duction of apoptosis following mitochondrial damage was of
no surprise as many previous studies confirmed the induction
of apoptosis after treating cells with various mitochondrial
damaging and anti-cancer agents in PDT [9]. PDT treatment
that causes mitochondrial damage promotes apoptosis
through the release of cytochrome C, AIF and other apopto-
genic proteins such as caspases [47]. Hypericin-mediated PDT
led to the initiation of apoptosis in a human hepatocellular
liver carcinoma cell line (HepG2) after analyzing Annexin V-
FITC/PI-stained cells using flow cytometry [48]. A large num-
ber of morphological changes including cell shrinkage, chro-
matin condensation, and nuclear fragmentation were
detected and identified as typical apoptotic features in three
cell lines (HeLa, HaCaT and MCF-7) when using cationic con-
jugated compounds containing ZnPC in PDT. And it was
concluded that those cells had undergone apoptosis, which
was detected 3 h after PDT [49].
Investigation into the expression of genes involved in cell
death pathways was done 3 h following PDT to finally assess
the efficacy of the conjugate in PDT and to determine which
genes were primarily affected. It transpired that out of the 84
genes examined, 4 genes (BAX, BCL-2, CASP-2 andULK-1)were
significantly up-regulated in the PDT treated cells. Bax is an
apoptosis regulator protein andmember of the Bcl-2 family. It
was among the first genes to be associated with pro-apoptotic
activity. Its activation has been linked to the loss in mito-
chondrial membrane potential and the release of cytochrome
C. Down-regulation or mutation of this protein leads to the
suppression of apoptosis [50,51]. It exits as a cytosolic protein
in normal cells, but upon induction of apoptotic signals it
undergoes a conformational change and becomes associated
with organelle membranes, in particular mitochondrial
membranes [52]. Curcumin-induced up-regulation of BAX and
cancer cell death through the mitochondrial-mediated
apoptotic pathway [33].
BCL-2 encodes for another Bcl-2 family member protein
that determines the commitment of cells to apoptosis [53].
Bcl-2 (B-cell lymphoma 2) regulates apoptosis by inducing or
inhibiting apoptosis but it is principally considered as an anti-
apoptotic effector and classified as an oncogene. In response
to mitochondrial damage, release of cytochrome C, caspase
activation and additional apoptotic events, BCL-2 is overex-
pressed to control those events [54].
Caspase 2 (CASP-2) is an apoptosis-related cysteine pepti-
dase and involved in the initiation of apoptosis by partici-
pating in the formation of the CARD domain, RIP-associated
Ich-1/Ced-3-homologue protein with a death domain (RAIDD),
apoptosis repressor with caspase recruitment domain (ARC),
and death effector filament-forming Ced-4-like apoptosis
protein (DEFCAP). Nuclear damage is critically important for
the expression of caspase-2 [55]. Additionally, caspase-2 can
interact with the p53-induced protein with a death domain to
form the PIPPosome, which is an activation platform for other
Fig. 9 The primary response of MPDC-mediated PDT on the expression of genes involved in cell death pathways was the up-
regulation of Ulk-1, Bax, Casp-2 and Bcl-2 genes. The Ulk-1 protein protonates and activates the FIP200. ULK is part of a protein
complex containing Atg13, Atg17 and FIP200 (autophagosome), which drives the subsequent cellular damage and death. The
Bax protein directly affects the mitochondria while the Cas-2 protein is activated by reactive oxygen species (ROS) and then
Casp-2 transforms a mitochondrial damaging protein into its truncated and activated form (tBid). The p53-induced death
domain associated protein (PIDD) can also convert pro-Casp-2 into the active Casp-2. Apoptogenic proteins (such as
Cytochrome C) released from mitochondria participate in the assemblage of the apoptosome, activation of other effectors
(Casp-3/6/7) and cell death. Mitochondrial damage and depolarization induce change in cellular ATP levels, activation of the 50
adenosine monophosphate activated protein kinase (AMPK) and AMPK-induced cell death. This cell death response stimulates
Bcl-2 protein to prevent further cell damage.
b i om e d i c a l j o u r n a l 4 1 ( 2 0 1 8 ) 2 5 4e2 6 4262proteases [56,57]. Robertson and colleagues (2002) found that
caspase-2 additionally induces genetic damage and the in-
duction of mitochondrial apoptotic pathway [46].
The fourth gene that was up-regulated, ULK-1 is associated
with autophagy, which is both a survival and cell death
mechanism. The ULK-1 gene is also known as the autophagy
initiation kinase Unc-51-like kinase (ULK1)/ATG1. Ulk-1 is an
autophagy initiator protein, which is indispensable for auto-
phagic complex formation [58]. This complex consists of ulk-1,
atg-13 and atg-17 and the complex leads to the formation of
autophagosomes in the absence of mammalian target of
rapamycin (mTOR) signal [59,60]. Autophagy has a cell death
role and it was demonstrated that Ulk-1 also plays a role in
ATP depletion and death in the presence of both PARP1 ac-
tivity and H2O2 (vigorous damage). And the same study
showed autophagy pro-death activity of Ulk-1 in response to
ROS generation [61]. The schematic representation of the
induced gene expression and cell death events of this present
study is presented in Fig. 9.Summary
The search for better and ideal PSs is indisputably encouraged.
Combining AuDENPs and ZnPcSmix yielded a successful and
stable hybrid agent with potent photodynamic abilities. The
MPDC was able to induce subsequent cytodamaging effects.
MCF-7 cells became sensitive to the treatment after PDT and
the subsequent cellular damage included increasedcytotoxicity, increased caspase activity, promotion of
apoptotic-like events and upregulation of genes involved in
apoptotic pathways. Conjugation could be considered as a
way to improve the therapeutic outcomes of individual and
less effective therapeutic agents to achieve better targeted
therapy or better delivery to cancer cells, and increased cancer
cell sensitivity to treatment.
The work presented in this paper is an in vitro study to
determine the cellular response and mechanism of this new
MPDC. Results presented here clearly indicate the therapeutic
potential that this compound hold. However, to realize the
clinical potential, in vivo and clinical trials will be performed in
future.Conflicts of interest
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